ES2402956T3 - Péptido con formación de dímeros reducida - Google Patents

Péptido con formación de dímeros reducida Download PDF

Info

Publication number
ES2402956T3
ES2402956T3 ES08788347T ES08788347T ES2402956T3 ES 2402956 T3 ES2402956 T3 ES 2402956T3 ES 08788347 T ES08788347 T ES 08788347T ES 08788347 T ES08788347 T ES 08788347T ES 2402956 T3 ES2402956 T3 ES 2402956T3
Authority
ES
Spain
Prior art keywords
peptide
seq
peptides
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08788347T
Other languages
English (en)
Spanish (es)
Inventor
Roderick Peter Hafner
Paul Laidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2402956(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715949A external-priority patent/GB0715949D0/en
Priority claimed from GB0716224A external-priority patent/GB0716224D0/en
Priority claimed from GB0723337A external-priority patent/GB0723337D0/en
Application filed by Circassia Ltd filed Critical Circassia Ltd
Application granted granted Critical
Publication of ES2402956T3 publication Critical patent/ES2402956T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
ES08788347T 2007-08-15 2008-08-15 Péptido con formación de dímeros reducida Active ES2402956T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0715949 2007-08-15
GB0715949A GB0715949D0 (en) 2007-08-15 2007-08-15 Peptide with improved solubility
GB0716224 2007-08-20
GB0716224A GB0716224D0 (en) 2007-08-20 2007-08-20 Peptides for vaccine
GB0723337A GB0723337D0 (en) 2007-11-28 2007-11-28 Peptide with reduced dimer formation
GB0723337 2007-11-28
PCT/GB2008/002779 WO2009022155A2 (en) 2007-08-15 2008-08-15 Peptide with reduced dimer formation

Publications (1)

Publication Number Publication Date
ES2402956T3 true ES2402956T3 (es) 2013-05-10

Family

ID=40134075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08788347T Active ES2402956T3 (es) 2007-08-15 2008-08-15 Péptido con formación de dímeros reducida

Country Status (23)

Country Link
US (7) US9340580B2 (enExample)
EP (4) EP2397154B1 (enExample)
JP (3) JP5697447B2 (enExample)
KR (1) KR101699554B1 (enExample)
CN (2) CN103272227B (enExample)
AT (1) ATE482721T1 (enExample)
AU (1) AU2008288283B2 (enExample)
BR (1) BRPI0815395A2 (enExample)
CA (1) CA2696563A1 (enExample)
CY (2) CY1110981T1 (enExample)
DE (1) DE602008002810D1 (enExample)
DK (2) DK2083856T3 (enExample)
EA (2) EA023303B1 (enExample)
ES (1) ES2402956T3 (enExample)
HR (2) HRP20130270T1 (enExample)
IL (1) IL203943A (enExample)
MX (1) MX2010001779A (enExample)
NZ (2) NZ583361A (enExample)
PL (1) PL2083856T3 (enExample)
PT (2) PT2397154E (enExample)
SI (2) SI2083856T1 (enExample)
WO (4) WO2009022156A2 (enExample)
ZA (2) ZA201001054B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
ES2402956T3 (es) 2007-08-15 2013-05-10 Circassia Limited Péptido con formación de dímeros reducida
EP2331124A1 (en) * 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
EP2153841B2 (en) 2008-08-15 2015-11-11 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN103784952B (zh) * 2009-02-05 2016-08-17 切尔卡西亚有限公司 用于疫苗的草肽
WO2011043538A2 (ko) 2009-10-08 2011-04-14 주식회사이언메딕스 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도
CN105061571A (zh) * 2010-01-14 2015-11-18 默克专利股份公司 因脯氨酸残基突变而具有降低变应原性的真禾本科第5组变应原的变体
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
EP3662916A1 (en) * 2010-06-03 2020-06-10 ALK-Abelló A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
US20130259884A1 (en) * 2010-09-24 2013-10-03 Alergenetica Sl Peptides
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
DK2721051T3 (en) * 2011-06-15 2018-03-05 Asit Biotech S A A PROCEDURE FOR THE PREPARATION OF HYDROOLIZED ALLERGENS
CN109172819A (zh) 2011-07-29 2019-01-11 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
DK2914286T3 (da) 2012-10-30 2021-11-08 Aravax Pty Ltd Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf
CA2910584A1 (en) 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
US20160130311A1 (en) * 2013-06-05 2016-05-12 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
JP6300907B2 (ja) * 2013-06-06 2018-03-28 アネルギ エスアー イエダニアレルギーの処置のための連続したオーバーラップペプチド
KR20160075532A (ko) * 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CA2933552A1 (en) * 2013-12-23 2015-07-02 Alk-Abello A/S Peptide combinations and uses thereof in treating dust mite allergy
AU2015239770B2 (en) 2014-03-31 2020-07-02 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses thereof
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
EP3556778A1 (en) * 2015-03-30 2019-10-23 Osaka University Immunizing peptide, method for producing immunizing peptide, pharmaceutical composition for immune disorders containing same, and method for treating immune disorders
CN108136000B (zh) 2015-09-30 2022-11-08 勃林格殷格翰动物保健有限公司 经改良的模块化抗原转运分子及其在动物中的用途
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11382934B2 (en) 2017-07-18 2022-07-12 Before Brands, Inc. Methods for making mixed allergen compositions
SG11202002310UA (en) * 2017-09-18 2020-04-29 Sutro Biopharma Inc Anti- folate receptor alpha antibody conjugates and their uses
CN108078891B (zh) * 2017-12-28 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的保湿修复洗面奶
CN107970199B (zh) * 2018-01-03 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的牙膏
CA3127337A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044532B1 (en) 1980-07-18 1986-04-23 E.I. Du Pont De Nemours And Company Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US4906564A (en) * 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
EP0765936A1 (en) * 1987-06-17 1997-04-02 Institute For Child Health Research Cloning of mite allergens
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ES2013359A6 (es) 1988-11-04 1990-05-01 Corporacion Biolog Farmaceutic Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
AU650249B2 (en) 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
DK0548200T3 (da) 1990-09-11 1999-10-25 Inst Child Health Research Kloning og sekventering af allergener fra dermatophagoides (husstøvmide)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
JP2632603B2 (ja) 1991-03-12 1997-07-23 アサヒビール株式会社 ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド
US6982326B1 (en) * 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
EP0623168B1 (en) * 1991-10-16 2009-09-30 Merck Patent GmbH T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
WO1994004572A1 (fr) 1992-08-14 1994-03-03 Torii & Co., Ltd. Peptide allergene
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
FI954269A0 (fi) 1993-03-12 1995-09-12 Immunologic Pharma Corp Raiheinäsiitepölyallergeenin T-soluepitoopit
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
JPH09501043A (ja) * 1993-04-14 1997-02-04 イミュロジク ファーマスーティカル コーポレイション Ｄｅｒｍａｔｏｐｈａｇｏｉｄｅｓ（室内塵ダニ）由来の主要アレルゲンのｔ細胞エピトープ
WO1994027634A1 (en) 1993-06-02 1994-12-08 Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
JPH09504167A (ja) 1993-08-13 1997-04-28 イミュロジック ファーマスーティカル コーポレイション ドクムギ花粉アレルゲンのｔ細胞エピトープ
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
US5820862A (en) * 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1995028424A1 (en) * 1994-04-14 1995-10-26 Immulogic Pharmaceutical Corporation Pharmaceutical peptide formulations for treatment of dust mite allergy
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE19545662C2 (de) * 1995-12-07 1998-11-26 Mannesmann Sachs Ag Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung
CA2247009C (en) 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
CN1283997A (zh) 1997-12-22 2001-02-14 人类基因组科学公司 角质形成细胞生长因子－2制剂
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
KR100919914B1 (ko) * 2000-11-16 2009-10-06 알크-아벨로 에이/에스 신규한 돌연변이체 알레르겐
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
JP4812951B2 (ja) * 2001-03-21 2011-11-09 一般財団法人化学及血清療法研究所 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法
GB0108752D0 (en) 2001-04-06 2001-05-30 Isis Innovation Peptide epitopes and uses thereof
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
AUPR775401A0 (en) * 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
EP2322165A1 (en) 2001-11-13 2011-05-18 Genentech, Inc. Apo2 ligand/TRAIL formulations
JP4874522B2 (ja) * 2001-12-05 2012-02-15 サーカッシア リミテッド 免疫療法および系
AUPS148202A0 (en) * 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
RU2324704C2 (ru) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
US20040071718A1 (en) * 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
JP2007524583A (ja) 2003-03-07 2007-08-30 ロンドン・ヘルス・サイエンシズ・センター・リサーチ・インコーポレーテッド 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
EP1636261B1 (en) 2003-06-26 2007-08-01 MERCK PATENT GmbH Thrombopoietin proteins with improved properties
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
CA2545458A1 (en) 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1756150A2 (en) 2004-04-23 2007-02-28 Novozymes A/S Group 1 mite polypeptide variants
WO2005121166A1 (en) * 2004-06-10 2005-12-22 Monash University Novel immunointeractive molecules and uses thereof
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
CA2581487C (en) * 2004-09-27 2013-07-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Isocyclomaltooligosaccharide (s), isocyclomaltooligosaccharide-forming enzyme, their preparation and uses
KR20070100832A (ko) 2005-02-01 2007-10-11 아테뉴온, 엘엘씨 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
DE602006014846D1 (de) * 2005-09-15 2010-07-22 Alk Abello As Verfahren zur quantifizierung von allergenen
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GB0609121D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
ES2402956T3 (es) 2007-08-15 2013-05-10 Circassia Limited Péptido con formación de dímeros reducida
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders

Also Published As

Publication number Publication date
CN103272227A (zh) 2013-09-04
CN101820907B (zh) 2013-05-01
CY1110981T1 (el) 2015-06-11
CA2696563A1 (en) 2009-02-19
EP2397154A2 (en) 2011-12-21
EP2190473B1 (en) 2013-01-16
JP2010536333A (ja) 2010-12-02
BRPI0815395A2 (pt) 2015-02-10
DE602008002810D1 (de) 2010-11-11
EP2397154A3 (en) 2012-04-04
EP2397154B1 (en) 2015-07-15
PT2083856E (pt) 2010-12-23
US20170157226A1 (en) 2017-06-08
WO2009022154A2 (en) 2009-02-19
US20100260805A1 (en) 2010-10-14
EP2286833A3 (en) 2011-09-14
PL2083856T3 (pl) 2011-04-29
SI2083856T1 (sl) 2011-02-28
ZA201001056B (en) 2011-04-28
NZ583362A (en) 2012-06-29
HRP20100662T1 (hr) 2011-01-31
WO2009022157A3 (en) 2009-06-04
ATE482721T1 (de) 2010-10-15
KR20100068252A (ko) 2010-06-22
US8551493B2 (en) 2013-10-08
AU2008288283A1 (en) 2009-02-19
US20130336999A1 (en) 2013-12-19
WO2009022154A3 (en) 2009-06-04
ZA201001054B (en) 2011-04-28
IL203943A (en) 2013-05-30
EP2286833A2 (en) 2011-02-23
JP6040207B2 (ja) 2016-12-07
WO2009022155A2 (en) 2009-02-19
KR101699554B1 (ko) 2017-01-25
EA018110B1 (ru) 2013-05-30
HK1164700A1 (en) 2012-09-28
DK2190473T3 (da) 2013-03-25
US20110123558A1 (en) 2011-05-26
SI2190473T1 (sl) 2013-05-31
DK2083856T3 (da) 2011-01-24
JP2017061455A (ja) 2017-03-30
US20160289281A1 (en) 2016-10-06
JP2015057393A (ja) 2015-03-26
CN101820907A (zh) 2010-09-01
EP2083856A2 (en) 2009-08-05
MX2010001779A (es) 2010-07-06
EP2190473A2 (en) 2010-06-02
JP5697447B2 (ja) 2015-04-08
EA201070271A1 (ru) 2010-12-30
US9340580B2 (en) 2016-05-17
HK1132194A1 (en) 2010-02-19
EA023303B1 (ru) 2016-05-31
HRP20130270T1 (hr) 2013-04-30
WO2009022156A3 (en) 2009-04-30
WO2009022157A2 (en) 2009-02-19
US9744222B2 (en) 2017-08-29
EP2083856B1 (en) 2010-09-29
AU2008288283B2 (en) 2013-01-31
US8652485B2 (en) 2014-02-18
EA201070270A1 (ru) 2010-08-30
NZ583361A (en) 2012-10-26
US20100298239A1 (en) 2010-11-25
PT2397154E (pt) 2015-10-29
CY1116828T1 (el) 2017-03-15
WO2009022156A2 (en) 2009-02-19
CN103272227B (zh) 2014-12-10
WO2009022155A3 (en) 2009-06-04
US20140186403A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
ES2402956T3 (es) Péptido con formación de dímeros reducida
ES2378870T3 (es) Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
CN102227214B (zh) 二聚体形成减少的组合物
ES2353360T3 (es) Combinaciones de péptidos para vacunas contra la alergia a los gatos.
JP5705113B2 (ja) Ｉｌ−１０産生の刺激のためのアレルゲン由来のｔ細胞抗原
ES2573651T3 (es) Péptidos para vacunas contra la alergia al abedul
ES2353362T3 (es) Péptidos para insensibilización contra alergenos.